The aim of this study is to evaluate the influence of immunosuppressants on in-hospital mortality from sepsis. Methods: Using data of the Health Insurance Review & Assessment Service, we collected data from patients who were admitted to the hospital due to sepsis from 2009 to 2013. Based on drugs commonly used for immunosuppression caused by various diseases, patients were divided into three groups; immunosuppressant group, steroid-only group, and control group. Patients with no history of immunosuppressants or steroids were assigned to the control group. To identify risk factors of in-hospital mortality in sepsis, we compared differences in patient characteristics, comorbidities, intensive care unit (ICU) care requirements, and immunodeficiency profiles. Subgroup analysis according to age was also performed. Results: Of the 185,671 included patients, 13,935 (7.5%) were in the steroid-only group and 2,771 patients (1.5%) were in the immunosuppressant group. The overall in-hospital mortality was 38.9% and showed an increasing trend with age. The steroid-only group showed the lowest in-hospital mortality among the three groups except the patients younger than 30 years. The steroid-only group and immunosuppressant group received ICU treatment more frequently (p < 0.001), stayed longer in the hospital (p < 0.001), and showed higher medical expenditure (p < 0.001) compared to the normal group. Univariate and multivariate analyses revealed that age, male gender, comorbidities (especially malignancy), and ICU treatment had a significant effect on in-hospital mortality. Conclusions: Despite longer hospital length of stay and more frequent need for ICU care, the in-hospital mortality was lower in patients taking immunosuppressive drugs than in patients not taking immunosuppressive drugs.
Introduction
Sepsis is a leading cause of complications and death in intensive care settings, and its treatment demands enormous medical resources. The incidence of sepsis is still increasing, and the efforts to improve outcomes for sepsis patients are underway in medical institutions worldwide. Among them are the Surviving Sepsis Campaign and the Global Sepsis Alliance. [1, 2] As a result, the mortality associated with sepsis has significantly declined. [1, 3] However, the absolute mortality rate is still high, hovering between 25% and 40%. [4] [5] [6] The risk factors of sepsis mortality include old age, chronic comorbidity, immunosuppression, blood-borne pathogens and non-antibiotic therapy. [6] [7] [8] [9] In particular, the presence of immunosuppression has steadily increased in sepsis patients over the last two decades, calling for investigations. [7, 8] However, such investigations have limitations to conduct because the cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. by their approach. [10, 11] Authors in this study investigated the incidence of in-hospital mortality and associated risk factors in sepsis patients based on epidemiological data of the two groups of sepsis patients on either steroid or non-steroid suppressive drugs and those not on suppressive drugs.
Materials and Methods
This study involved the analysis of medical information 
Results
A total of 185,671 sepsis patients were admitted to hospital from 2009 to 2013. Of those, 13,935 (7.5%) were on steroids only while 2,771 (1.5%) were on non-steroid suppressive drugs. The mean age of patients was 68.4, and the ratio of male to female was 1.1:1. By comorbidity in a population of patients, diabetes (42.6%) was the most common comorbid condition, followed by hypertension (39.4%). Malignant tumor was also found in 6.5% of patients. By the reason underlying suppressive drug use, leukemia (9.1%) was the most common reason, followed by organ transplantation, rheumatoid arthritis, Crohn's disease, ulcerative colitis and atopic dermatitis ( Table 1 ). The mean age of the Suppression group was lower at 51.2 years, but its ratio of male to female was higher at 1.3:1, compared with the Steroid and control groups. The distribution of comorbidities also showed differences among the groups: the presence of hypertension, diabetes, cerebrovascular disease was higher in the Steroid group whereas chronic liver and kidney diseases along with malignant tumor were significant in the Suppression group (Table 2 ).
The analysis of distribution of immunosuppressive state male patients was slightly higher than the number of female patients in all age groups except the 80+ age group (Table 3) .
Of total patients, 38.9% had in-hospital mortality, which can be further broken down into 31.0% in the Steroid group, 30.5% in the Suppression group and 39.7% in the control group. In-hospital mortality increased with age in the all groups. In the 18-29 age sub-groups, the in-hospital mortality rate was 16.0%, 27.7% and 13.4% respectively, in the Steroid, Suppression and Control groups. In the 80+ age group, the in-hospitality mortality rate was 39.4%, 61.1%
and 51.0%, respectively in the three groups in the same order. The in-hospital mortality was lower in the Steroid group, compared with the Suppression and Control groups, in older groups beyond the 18-29 age group (p < 0.001) (Fig. 1) .
Of total patients, 54,119 (29.2%) were admitted to ICU, and the proportion of patients admitted to ICU was significantly higher in the Steroid and Suppression groups than the control group (p < 0.001). While the mean length of stay was 23.7 days for total patients, the Steroid and Suppression groups showed 39.1 and 39.3 days, respectively, meaning that their hospital stay was significantly higher than the control group. The mean total hospital cost of these two groups was also as much as 2-4 times higher than the control group (p < 0.001) ( disease, chronic kidney disease, cerebrovascular disease and malignant tumor. The odds ratio of malignancy was higher than those for other comorbidities. The use of suppressive drugs including steroids turned out to be a protective factor reducing the risk of hospital mortality (Table 5) .
Discussion
This study explored the presence of immunosuppression and subsequent mortality in sepsis patients on suppressive drugs based on nationwide medical information collected into the HIRA database under the national medical system.
Based on medical information for the period from 2009
to 2013, the total hospital mortality was 38.9% in total sepsis patients. By group, the mortality was 31.0% and 30.5%, respectively, in the Steroid and Suppression groups, which were significantly lower than 39.7% of patients in the control group. However, the admission to ICU, length of stay and total hospital cost were significantly higher in patients on suppressive drugs than those in the control group. According to large scale international studies, sepsis 
Fig. 1.
In-hospital mortality of sepsis patients. The hospital mortality was positively correlated with age in all age groups, and the mortality rate was lower in the Steroid group, compared with the Suppression and control groups, in the older groups beyond the 18-29 age group, (p < 0.001).
has a mortality rate of 25% to 40% in 2000. A wide range in mortality reflects different levels of sepsis found in the respective studies. [4] [5] [6] [14] [15] [16] This study came up with a relatively higher sepsis mortality rate despite the fact that it was conducted somewhat lately and it included all patients presenting sepsis regardless of their severity.
Sepsis patients in an immunosuppressed state tend to develop non-specific and diverse signs and symptoms, compared to non-immunospressed patients, making it hard to define their severity based on the screening criteria. For instance, these patients did not increase white blood cells or C-reactive protein, which are commonly found in sepsis patients, resulting in failure of early diagnosis and poor prognosis. [17, 18] Tolsma suggested that an immunosuppressed state increases the risk of short-term mortality in sepsis patients. His study was more comprehensive than other studies because it addressed immunosuppressed states caused by a wide range of diseases, including white blood cell, inborn immune deficiency, solid tumor and leukemia and suggested an immunosuppressed state as a risk factor influencing prognosis for sepsis. [19] Steroid drug is commonly prescribed for a variety of conditions due to is anti-inflammatory and immunosuppressive properties, which inhibit the synthesis of proinflammatory cytokines or cyclo-oxygenase. However, prolonged use or overuse of steroid drug can result in excessive immunosuppression, which in turn increases the risk of infection. However, early signs of infection are not easily detectable. [20, 21] Steroid-induced risk of various infections such as tuberculosis and oral candidiasis has been reported. A study reported the risk of infection was 1.6 times higher in patients on steroid drug, compared with the control group. [20, [22] [23] [24] The The increase in the mean hospital costs as a result of longer period of stay can be explained in the same way. Also, the cause of death in sepsis patients may be other conditions (aggravated comorbidity or complication) than sepsis itself because the cause of death is not correctly described in some cases of insurance claim. That is, sepsis mortality may be more affected by condition-dependent immune deficiency than drug-induced immunosuppression, although further studies are necessary to prove this assumption.
In this study, in-hospital mortality increased with age in all groups, although the presence of immunosuppression varied among different age groups. This finding is in agreement with previous studies in which the onset and severity of sepsis and sepsis mortality were positively correlated with age although actual rates vary among countries. [14, 15, 30] This study however has the following limitations: first, to select subjects, this study relied on the category code of sepsis that physicians enter for patients to be discharged.
However, entered codes are not monitored, and physicians may not add a new code for patients who were already assigned another category code based on principal diagnosis.
This means that the sepsis mortality found in this study may be underestimated because patients who developed sepsis after infection or immune-related comorbidity may not be correctly compiled due to human negligence. Secondly, the results of this study cannot be generalized to a population taking suppressive drugs to determine their sepsis mortality because the study population was defined as sepsis patients taking suppressive drugs and their in-hospital mortality was investigated. We could not confirm the well-established conclusion that immunosuppressed patients are more vulnerable to sepsis than those with healthy immune systems. Thirdly, this study addressed drug-induced immunosuppression only and did not explore condition-induced immunosuppression.
Fourthly, the presence of accompanying septic shock and severity of sepsis in each group were not analyzed due to a lack of necessary information. Lastly, we cannot assure that all patients were given a professional care according to standard treatment guidelines such as the Survival Sepsis
Guidelines because we cannot confirm such information from the database.
In conclusion, of total sepsis patients, 9.0% were on either steroid or non-steroid suppressive drugs, and their in-hospital mortality was nearly 31%. However, this study did not find a close relationship between immunosuppressed drug use and mortality that is well established in the literature. Further studies are necessary to verify effects of immunosuppressed states.
